Почетна › Рак на простата › Њујорк

Клинички испитувања за Рак на простата во Њујорк

126 студии за Рак на простата бараат учесници на локации во Њујорк.

Градови во Њујорк

Официјален текст на студијата (англиски)

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Research Site, New York
Research Site, New York

Се регрутираФаза 1/2

Возраст од 18 до 130 · Сите полови · Ажурирано 5.10.2026 · NCT05417594

A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

James J. Peters VA Medical Center, Bronx, NY, The Bronx

Се регрутираФаза 2

Возраст 18 и постари · Мажи · Ажурирано 5.10.2026 · NCT05593497

Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients

Kings County Hopsital Center, Brooklyn
Queens Cancer Center of Queens Hospital, Jamaica
Memorial Sloan Kettering at Ralph Lauren Center (Limited Protocol Activities), New York
и уште 1

Се регрутира

Возраст 18 и постари · Сите полови · Ажурирано 5.10.2026 · NCT04751435

A Study of Mental Health Care in People With Cancer

Memorial Sloan Kettering Cancer Center, New York

Се регрутира

Возраст 65 и постари · Сите полови · Ажурирано 5.10.2026 · NCT06037954

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
Icahn School of Medicine at Mount Sinai, New York
и уште 2

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT06465069

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Columbia University Medical Center, New York
Memorial Sloan Kettering, New York

Се регрутираФаза 1/2

Возраст 12 и постари · Сите полови · Ажурирано 2.10.2026 · NCT04585750

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

Roswell Park Cancer Institute, Buffalo
Memorial Sloan Kettering Commack, Commack
Guthrie Cortland Memorial Hospital, Cortland
и уште 5

Се регрутираФаза 3

Возраст 18 и постари · Мажи · Ажурирано 2.10.2026 · NCT06931340

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

Roswell Park Cancer Institute, Buffalo
Memorial Sloan Kettering Commack, Commack
Memorial Sloan Kettering Westchester, Harrison
и уште 4

Се регрутираФаза 3

Возраст 18 и постари · Мажи · Ажурирано 2.10.2026 · NCT07200830

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

Roswell Park Cancer Institute, Buffalo
Mount Sinai Hospital, New York

Се регрутираФаза 2

Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT06632977

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Queens Hospital Center, Jamaica
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Stony Brook University Medical Center, Stony Brook

Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери

Возраст од 40 до 75 · Сите полови · Ажурирано 2.10.2026 · NCT05334069

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Roswell Park Cancer Institute IDS, Buffalo
Memorial Sloan Kettering Hospital, New York

Се регрутираФаза 2

Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT06172478

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Memorial Sloan Kettering Commack, Commack
Memorial Sloan Kettering Westchester, Harrison
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
и уште 3

Се регрутираФаза 2

Возраст 18 и постари · Сите полови · Ажурирано 30.9.2026 · NCT03866382

Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix

Crystal Run Healthcare, Middletown

Се регрутираНабљудувачка студија

Возраст од 40 до 75 · Мажи · Ажурирано 28.9.2026 · NCT07543757

Precision-Based Genomics in Prostate Cancer

Memorial Sloan Kettering Cancer Center, New York
Mount Sinai Hospital, New York
Weill Cornell Medicine, New York

Се регрутираНабљудувачка студија

Возраст од 18 до 120 · Мажи · Ажурирано 28.9.2026 · NCT04706663

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

Herbert Irving Comprehensive Cancer Center Columbia University Medical Center, New York

Се регрутираФаза 1

Возраст 18 и постари · Мажи · Ажурирано 28.9.2026 · NCT06095089

A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer

Columbia University Medical Center, New York

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07319871

Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

Memorial Sloan Kettering Cancer Center, Long Island City
Associated Medical Professionals, Syracuse

Се регрутираФаза 1/2

Возраст 18 и постари · Мажи · Ажурирано 25.9.2026 · NCT06800313

A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer

Associated Medical Professionals, Syracuse

Се регрутираФаза 2

Возраст 18 и постари · Мажи · Ажурирано 25.9.2026 · NCT07832292

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Associated Medical Professionals - Urology ( Site 0081), Syracuse

Се регрутираФаза 3

Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06136650

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

Research Site, New York

Се регрутираФаза 1/2

Возраст од 18 до 130 · Мажи · Ажурирано 25.9.2026 · NCT07181161

A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

Columbia University Medical Center, New York

Се регрутираФаза 1

Возраст 18 и постари · Мажи · Ажурирано 25.9.2026 · NCT07082920

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

MSK Commack, Commack
MSKCC-Westchester (500 Westchester Ave.), Harrison
Integrated Medical Professionals, Lake Success
и уште 10

Се регрутираФаза 3

Возраст 18 и постари · Мажи · Ажурирано 24.9.2026 · NCT07028853

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

Mount Sinai Hosp Med School, New York
Associated Med Professionals of NY, Syracuse
Montefiore Medical Center, The Bronx

Се регрутираФаза 2/3

Возраст од 18 до 100 · Мажи · Ажурирано 22.9.2026 · NCT06780670

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

New York University (NYU) Langone Medical Center, New York
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York

Се регрутираФаза 1

Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07114601

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Hematology Oncology Association of Central New York, East Syracuse
Memorial Sloan Kettering Cancer Center, New York

Се регрутираФаза 3

Возраст 18 и постари · Мажи · Ажурирано 22.9.2026 · NCT07213674

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

Bassett Medical Center, Cooperstown
Weill Cornell Medicine NY-Presb, New York
University of Rochester Medical Ctr, Rochester
и уште 2

Се регрутираФаза 3

Возраст од 18 до 100 · Мажи · Ажурирано 22.9.2026 · NCT06855277

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

Research Site, New York
Research Site, Syracuse

Се регрутираФаза 3

Возраст 18 и постари · Мажи · Ажурирано 18.9.2026 · NCT06952803

Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer

Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities), Commack
Memorial Sloan Kettering at Westchester (Limited Protocol Activities), Harrison
Weill Cornell Medical Center (Data Collection Only), New York
и уште 2

Се регрутираФаза 3

Сите возрасти · Мажи · Ажурирано 18.9.2026 · NCT07548164

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY, New York

Се регрутираФаза 2

Возраст 18 и постари · Мажи · Ажурирано 17.9.2026 · NCT04038502

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Icahn School of Medicine at Mount Sinai ( Site 0009), New York
Great Lakes Cancer Care ( Site 0047), Williamsville

Се регрутираФаза 3

Возраст 18 и постари · Мажи · Ажурирано 17.9.2026 · NCT06925737

A Study of Changes to Prostate Procedures

Memorial Sloan Kettering Suffolk-Commack (Consent only), Commack
Memorial Sloan Kettering Westchester (Consent Only), Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
и уште 1

Се регрутираФаза 3

Возраст 18 и постари · Мажи · Ажурирано 15.9.2026 · NCT06986083

PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

Memorial Sloan Kettering Cancer Center, New York

Се регрутираНабљудувачка студија

Возраст 18 и постари · Мажи · Ажурирано 15.9.2026 · NCT04995198

MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

Memorial Sloan Kettering Cancer Center, New York

Се регрутираФаза 2

Возраст 18 и постари · Мажи · Ажурирано 15.9.2026 · NCT06150417

The SUGAR Study; SBRT and Relugolix) for Prostate Cancer

Memorial Sloan Kettering Cancer Center, New York

Се регрутираФаза 2

Возраст 18 и постари · Мажи · Ажурирано 14.9.2026 · NCT06111781

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

Integrated Medical Professionals, New York

Се регрутира

Возраст 18 и постари · Мажи · Ажурирано 14.9.2026 · NCT06511141

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Albany Medical College, Department of Urology, Albany
Mount Sinai Doctors Urology Faculty Practice, New York

Се регрутираФаза 3

Возраст 18 и постари · Мажи · Ажурирано 11.9.2026 · NCT06056830

[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate or Salivary Gland Cancer

Memorial Sloan Kettering Commack (Consent only), Commack
Memorial Sloan Kettering Westchester (Consent only), Harrison
Memorial Sloan Kettering Cancer Center, New York
и уште 1

Се регрутира

Сите возрасти · Мажи · Ажурирано 11.9.2026 · NCT00588185

Transperineal Micro-ultrasound for the Detection of Prostate Cancer During Biopsy

Roswell Park Cancer Institute, Buffalo

Се регрутира

Возраст 18 и постари · Мажи · Ажурирано 11.9.2026 · NCT07075705

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

Northwell Health Imbert Cancer Center, Bay Shore
New York-Presbyterian/Brooklyn Methodist Hospital, Brooklyn
Sands Cancer Center, Canandaigua
и уште 19

Се регрутираФаза 3

Возраст 18 и постари · Мажи · Ажурирано 10.9.2026 · NCT05946213

Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer

NYU Langone Health, New York

Се регрутираФаза 2

Возраст 18 и постари · Мажи · Ажурирано 3.9.2026 · NCT07801664

Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.